Entyvio REMS Decision Explained
This article was originally published in RPM Report
Executive Summary
FDA approved Takeda’s Entyvio (vedolizumab) for Crohn’s and ulcerative colitis without a formal Risk Evaluation & Mitigation Strategy. In the review materials, the agency explains its decision.